Middle, pluractional, and progression-marker
Brill's Journal of Afroasiatic Languages and Linguistics · 22.06.2026 · 18 (1) · 193-239
DOI: 10.1163/18776930-01801009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brill's Journal of Afroasiatic Languages and Linguistics, erschienen am 22.06.2026. Verfasst von Iris Tanza-Kamil. Die Arbeit nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Afroasiatic t -morpheme is found in Akkadian (East-Semitic) with three distinct functions: a syncretic ‘Middle’, a pluractional, and a progression-marker. As a Middle, the morpheme may denote passive, reflexive/reciprocal, or noncausal functions. As a pluractional, it denotes iterative, frequentative, habitual, continuous, and distributive meanings. As a progression-marker, it typically links the marked event to a chain of perfective -marked events. No consensus has been reached thus far as to how this syncretic system came to be. This paper develops a semantic diachronic reconstruction, arguing that Middles of unergatives, which regularly derive atelic predicates, led to a first process of reanalysis wherein the t -morpheme became associated with general atelicity. From there on, by attaching to the imperfective , the morpheme developed from atelic > pluractional and by attaching to the perfective from atelic > progression-marker.
Zitieren
APA
Tanza-Kamil, I. (2026). Middle, pluractional, and progression-marker. Brill's Journal of Afroasiatic Languages and Linguistics, 18(1), 193-239. https://doi.org/10.1163/18776930-01801009
Vancouver
Tanza-Kamil I. Middle, pluractional, and progression-marker. Brill's Journal of Afroasiatic Languages and Linguistics. 2026;18(1):193-239. doi:10.1163/18776930-01801009
BibTeX
@article{TanzaKamil2026,
author = {Tanza-Kamil, Iris},
title = {Middle, pluractional, and progression-marker},
journal = {Brill's Journal of Afroasiatic Languages and Linguistics},
year = {2026},
volume = {18},
number = {1},
pages = {193--239},
doi = {10.1163/18776930-01801009}
}
EUVIMED